[go: up one dir, main page]

HUP0303258A3 - N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them - Google Patents

N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them

Info

Publication number
HUP0303258A3
HUP0303258A3 HU0303258A HUP0303258A HUP0303258A3 HU P0303258 A3 HUP0303258 A3 HU P0303258A3 HU 0303258 A HU0303258 A HU 0303258A HU P0303258 A HUP0303258 A HU P0303258A HU P0303258 A3 HUP0303258 A3 HU P0303258A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
nr2b antagonists
nmda
nonaryl
Prior art date
Application number
HU0303258A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23034191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0303258(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HUP0303258A2 publication Critical patent/HUP0303258A2/hu
Publication of HUP0303258A3 publication Critical patent/HUP0303258A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
HU0303258A 2001-02-23 2002-02-20 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them HUP0303258A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27110001P 2001-02-23 2001-02-23
PCT/US2002/005226 WO2002068409A1 (en) 2001-02-23 2002-02-20 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists

Publications (2)

Publication Number Publication Date
HUP0303258A2 HUP0303258A2 (hu) 2004-01-28
HUP0303258A3 true HUP0303258A3 (en) 2004-06-28

Family

ID=23034191

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303258A HUP0303258A3 (en) 2001-02-23 2002-02-20 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them

Country Status (33)

Country Link
US (2) US7217716B2 (hu)
EP (1) EP1379520B2 (hu)
JP (1) JP4179879B2 (hu)
KR (1) KR100849839B1 (hu)
CN (1) CN100567293C (hu)
AT (1) ATE324371T1 (hu)
AU (1) AU2002252053B2 (hu)
BG (1) BG108113A (hu)
BR (1) BR0207526A (hu)
CA (1) CA2438895A1 (hu)
CZ (1) CZ20032258A3 (hu)
DE (1) DE60210944T3 (hu)
DK (1) DK1379520T3 (hu)
EA (1) EA005974B1 (hu)
EC (1) ECSP034744A (hu)
EE (1) EE200300403A (hu)
ES (1) ES2261658T3 (hu)
GE (1) GEP20063741B (hu)
HR (1) HRP20030669A2 (hu)
HU (1) HUP0303258A3 (hu)
IL (2) IL157254A0 (hu)
IS (1) IS6902A (hu)
MX (1) MXPA03007621A (hu)
NO (1) NO20033732L (hu)
NZ (1) NZ527365A (hu)
PL (1) PL364625A1 (hu)
PT (1) PT1379520E (hu)
SI (1) SI1379520T1 (hu)
SK (1) SK10542003A3 (hu)
UA (1) UA75392C2 (hu)
WO (1) WO2002068409A1 (hu)
YU (1) YU64303A (hu)
ZA (1) ZA200306159B (hu)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100352A2 (en) * 2001-06-12 2002-12-19 Merck & Co., Inc. Nr2b receptor antagonists for the treatment or prevention of migraines
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE366045T1 (de) * 2002-03-15 2007-07-15 Ciba Sc Holding Ag Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
AU2003231359B2 (en) 2002-04-16 2009-04-30 Teijin Limited Piperidine derivatives having CCR3 antagonism
KR20040104596A (ko) 2002-04-25 2004-12-10 데이진 가부시키가이샤 Ccr3 길항 작용을 갖는 4,4-2치환 피페리딘 유도체
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
JP2004315511A (ja) * 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Mch受容体アンタゴニスト
UA81319C2 (en) * 2003-06-04 2007-12-25 Merck & Co Inc 3-fluoro-piperidines as nmda/nr2b antagonists
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
CA2533377C (en) 2003-07-30 2012-11-27 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2005075439A1 (en) 2004-02-03 2005-08-18 Astrazeneca Ab Quinazoline derivatives
RU2006139258A (ru) 2004-04-08 2008-05-20 Таргеджен, Инк. (US) Бензотриазиновые ингибиторы киназ
CA2575430A1 (en) * 2004-08-03 2006-02-16 Merck & Co., Inc. 1,3-disubstituted heteroaryl nmda/nr2b antagonists
US20080153917A1 (en) * 2004-09-10 2008-06-26 Ucb Pharma, S.A. Sigma Receptor Ligands
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
CA2613235A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
CN101346368A (zh) * 2005-12-21 2009-01-14 詹森药业有限公司 作为α2C-肾上腺素受体拮抗剂的取代的吡嗪酮衍生物
US7935706B2 (en) 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
BRPI0709699A2 (pt) * 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inibiÇço da toxidez da alfa-sinucleina
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5179509B2 (ja) * 2006-12-08 2013-04-10 エフ.ホフマン−ラ ロシュ アーゲー 置換ピリミジン類及びjnkモジュレーターとしてのこれらの使用
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
DK2148873T3 (da) * 2007-04-23 2012-11-26 Janssen Pharmaceutica Nv 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister
CA2682671C (en) 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
CN101835750B (zh) * 2007-08-22 2013-07-17 阿斯利康(瑞典)有限公司 环丙基酰胺衍生物
US20100249164A1 (en) * 2007-10-31 2010-09-30 Renger John J Modulation of sleep with nr2b receptor antagonists
MY150290A (en) 2008-02-07 2013-12-31 Boehringer Ingelheim Int Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
US8530474B2 (en) 2008-07-03 2013-09-10 Janssen Pharmaceutica Nv Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists
US8895562B2 (en) 2008-07-31 2014-11-25 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
BR112012020782A2 (pt) * 2010-02-18 2016-05-03 Astrazeneca Ab composto, e, processo para preparar um composto
TW201136898A (en) * 2010-02-18 2011-11-01 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
JP6001049B2 (ja) * 2011-03-31 2016-10-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Mps−1キナーゼ阻害剤としての置換ベンズイミダゾール類
US8722670B2 (en) * 2011-09-30 2014-05-13 Bristol-Myers Squibb Company Selective NR2B antagonists
CN104321057B (zh) 2012-04-20 2016-09-14 Ucb医药有限公司 用于治疗帕金森病的方法
JP2016028017A (ja) * 2012-12-13 2016-02-25 大正製薬株式会社 フッ素置換ピペリジン化合物
JP2017001954A (ja) * 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物
WO2015182724A1 (ja) * 2014-05-28 2015-12-03 トーアエイヨー株式会社 置換トロパン誘導体
AU2015271719A1 (en) * 2014-06-04 2016-12-01 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
AU2015317886A1 (en) * 2014-09-15 2017-03-09 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
WO2016100349A2 (en) * 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
EP3253761A4 (en) 2015-02-04 2018-06-20 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
US10584102B2 (en) 2015-05-11 2020-03-10 Basf Se Process for preparing 4-amino-pyridazines
EP3303323B1 (en) 2015-06-01 2020-01-08 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
CA3097740A1 (en) * 2018-02-23 2019-08-29 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Novel inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL265777A (hu) * 1960-06-09
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
EP0126087A1 (en) * 1982-09-24 1984-11-28 Beecham Group Plc Amino-azabicycloalkyl derivatives as dopamine antagonists
RU2099339C1 (ru) 1990-02-06 1997-12-20 Пфайзер Инк. Производные пиперидина
DK0554247T3 (da) 1990-05-10 2000-08-07 Pfizer Neurobeskyttende indolon og beslægtede derivater
US5189036A (en) 1990-06-20 1993-02-23 Schering Ag Imidazolylbenzoyl substituted heterocycles
EP0584192A1 (en) 1991-04-18 1994-03-02 Pfizer Inc. Prodrug esters of phenolic 2-piperidino-1-alkanols
WO1993002052A1 (en) 1991-07-17 1993-02-04 Pfizer Inc. 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994014776A2 (en) 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU6252794A (en) 1993-03-03 1994-09-26 Eli Lilly And Company Balanoids
JPH08508030A (ja) 1993-03-18 1996-08-27 メルク シヤープ エンド ドーム リミテツド ベンゾイミダゾール誘導体
AU3138595A (en) 1994-07-20 1996-02-16 Acea Pharmaceuticals, Inc. Haloperidol analogs and the use thereof
US5661161A (en) 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0742208A1 (en) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamide derivatives
MX9709112A (es) 1995-05-26 1998-02-28 Pfizer Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato.
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
EP0771779B1 (en) 1995-11-06 2002-05-02 Kuraray Co., Ltd. Process for producing acetals
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
EP0787493A1 (en) 1996-02-03 1997-08-06 F. Hoffmann-La Roche Ag Tetrahydroisoquinoline derivatives
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
AU2898297A (en) 1996-05-24 1998-01-05 Novartis Ag Use of substance p antagonists for treating social phobia
ES2271971T3 (es) 1996-07-25 2007-04-16 Biogen Idec Ma Inc. Inhibidores de la adhesion celular.
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0846683B1 (en) 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxy-piperidine derivatives
FR2758327B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles arylpiperazines derivees de piperidine
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
US6020347A (en) 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
AU1415099A (en) 1997-11-18 1999-06-07 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
DE19815026A1 (de) * 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
ES2261844T3 (es) 1998-08-07 2006-11-16 Applied Research Systems Ars Holding N.V. Mimeticos de la fsh para el tratamiento de la infertilidad.
DE19838300A1 (de) 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
JP3936844B2 (ja) 1999-04-13 2007-06-27 ビーエーエスエフ アクチェンゲゼルシャフト インテグリンレセプターリガンド
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds

Also Published As

Publication number Publication date
NO20033732D0 (no) 2003-08-22
MXPA03007621A (es) 2003-12-04
AU2002252053B2 (en) 2006-09-14
SK10542003A3 (sk) 2004-03-02
JP2004524314A (ja) 2004-08-12
ATE324371T1 (de) 2006-05-15
BG108113A (bg) 2005-04-30
PL364625A1 (en) 2004-12-13
IS6902A (is) 2003-07-31
EP1379520A1 (en) 2004-01-14
DE60210944T3 (de) 2015-07-23
US20020165241A1 (en) 2002-11-07
AU2002252053C1 (en) 2002-09-12
US7053089B2 (en) 2006-05-30
ECSP034744A (es) 2003-10-28
JP4179879B2 (ja) 2008-11-12
GEP20063741B (en) 2006-02-10
BR0207526A (pt) 2004-03-09
NZ527365A (en) 2005-08-26
WO2002068409A1 (en) 2002-09-06
EP1379520B1 (en) 2006-04-26
US20040209889A1 (en) 2004-10-21
PT1379520E (pt) 2006-08-31
UA75392C2 (en) 2006-04-17
US7217716B2 (en) 2007-05-15
CN100567293C (zh) 2009-12-09
DK1379520T3 (da) 2006-08-21
CZ20032258A3 (cs) 2004-01-14
DE60210944T2 (de) 2007-04-19
EA200300919A1 (ru) 2004-02-26
IL157254A0 (en) 2004-02-19
NO20033732L (no) 2003-10-22
YU64303A (sh) 2006-05-25
KR100849839B1 (ko) 2008-08-01
HUP0303258A2 (hu) 2004-01-28
EE200300403A (et) 2003-12-15
EP1379520B2 (en) 2014-04-09
EA005974B1 (ru) 2005-08-25
IL157254A (en) 2008-11-26
CA2438895A1 (en) 2002-09-06
SI1379520T1 (sl) 2006-08-31
HRP20030669A2 (en) 2005-06-30
CN1503793A (zh) 2004-06-09
KR20030076703A (ko) 2003-09-26
ZA200306159B (en) 2004-07-05
DE60210944D1 (de) 2006-06-01
ES2261658T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
HUP0303258A3 (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them
EP1390034A4 (en) NMDA / NR2B NONARYL-HETEROCYCLO AMIDYL N-SUBSTITUTE ANTAGONISTS
HUP0303651A3 (en) N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor and pharmaceutical compositions containing them
IL187604A0 (en) Pharmaceutical compositions containing an interleukin-6 antagonist
HUP0303325A3 (en) Pharmaceutical salts and pharmaceutical compositions containing them
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
HUP0101275A3 (en) Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
HUP0303108A3 (en) Substituted pyrazoles and pharmaceutical compositions containing them
HUP0400384A3 (en) Benzamidine derivative and pharmaceutical compositions containing them and their use
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
HUP0400048A3 (en) N-aroyl cyclic amines and pharmaceutical compositions containing them
IL158041A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL163117A (en) Indazole derivatives and pharmaceutical compositions containing the same
HUP0400052A3 (en) Carboxamide-substituted phenylurea derivatives and pharmaceutical compositions containing them and their use
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
HUP0203965A3 (en) Indazole compounds and pharmaceutical compositions containing them
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
HUP0500880A2 (en) Cxcr3 antagonists and pharmaceutical compositions thereof
HUP0402679A3 (en) Pyrrolidine and piperidine derivatives as nki antagonists and pharmaceutical compositions containing them
HUP0303825A3 (en) 1h-benzimidazole and 3h-imidazo-[4,5b]pyridine-derivatives, their use and pharmaceutical compositions containing them
HUP0400349A3 (en) Ccr5 antagonists useful for treating aids and pharmaceutical compositions containing them
IL156812A0 (en) Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
HUP0402019A3 (en) Piperidine derivatives useful as ccr5 antagonists and pharmaceutical compositions containing them
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
IL158671A0 (en) Benzyloxy derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees